TITLE

Interferon-Stimulated Gene 15 Conjugation Stimulates Hepatitis B Virus Production Independent of Type I Interferon Signaling Pathway In Vitro

AUTHOR(S)
Li, Yujia; Li, Shilin; Duan, Xiaoqiong; Chen, Yanzhao; Jiao, Baihai; Ye, Haiyan; Yao, Min; Chen, Limin
PUB. DATE
October 2016
SOURCE
Mediators of Inflammation;10/27/2016, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hepatitis B virus (HBV) is an important account of infectious hepatitis and interferon (IFN) remains one of the best treatment options. Activation of type I IFN signaling pathway leads to expressions of IFN-stimulated genes (ISGs) which play important roles in antiviral and immunomodulatory responses to HBV or hepatitis C virus (HCV) infection. Our previous studies indicated that ISG15 and its conjugation (ISGylation) were exploited by HCV to benefit its replication and persistent infection. This study was designed to assess the role of ISG15 and ISGylation in HBV infection in vitro. The levels of ISG15 and ISGylation were upregulated by ISG15 plasmid transfection into HepG2.2.15 cells. Decreased ISGylation was achieved by siRNA targeting UBE1L, the only E1 activating enzyme for ISGylation. Overexpression of ISG15 and subsequent ISGylation significantly increased the levels of HBV DNA in the culture supernatants although the intracellular viral replication remained unaffected. Silencing UBE1L, with decreased ISGylation achieved, abrogated this ISGylation-mediated promoting effect. Our data indicated that overexpression of ISG15 stimulated HBV production in an ISGylation-dependent manner. Identification of ISG15-conjugated proteins (either HBV viral or host proteins) may reveal promising candidates for further antiviral drug development.
ACCESSION #
119102486

 

Related Articles

  • Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro. Yong-Wen He; Chun-Xia Guo; Yan-Feng Pan; Cheng Peng; Zhi-Hong Weng; Reiser, Markus; Menne, Stephan; Gretch, David R. // World Journal of Gastroenterology;3/14/2008, Vol. 14 Issue 10, p1592 

    AIM: To explore the inhibitory effects of pokeweed antiviral protein seed (PAP-S) and PAP encoded by a eukaryotic expression plasmid on hepatitis B virus (HBV) replication in vitro. METHODS: HepG2 2.2.15 cells in cultured medium were treated with different concentrations of PAP-S. HBsAg, HBeAg...

  • siRNA Combinations Mediate Greater Suppression of Hepatitis B virus Replication in Mice. Li, Guiqiu; Fu, Lu; Jiang, Jinghong; Ping, Yuzhuo; Huang, Yanjun; Wang, Yongchen // Cell Biochemistry & Biophysics;Jul2014, Vol. 69 Issue 3, p641 

    Hepatitis B virus (HBV) infection is a major world-wide health problem. The major obstacles for current anti-HBV therapy are the low efficacy and the occurrence of drug resistant HBV mutations. Recent studies have demonstrated that combination therapy can enhance antiviral efficacy and overcome...

  • Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity. Jia, Xiaojuan; Bi, Yuhai; Li, Jing; Xie, Qing; Yang, Hanchun; Liu, Wenjun // Scientific Reports;5/29/2015, p10651 

    Porcine reproductive and respiratory syndrome (PRRS) has caused large economic losses in the swine industry in recent years. Current PRRS vaccines fail to effectively prevent and control this disease. Consequently, there is a need to develop new antiviral strategies. MicroRNAs play critical...

  • Human Cytomegalovirus Replication Is Strictly Inhibited by siRNAs Targeting UL54, UL97 or UL122/123 Gene Transcripts. Hamilton, Stuart T.; Milbradt, Jens; Marschall, Manfred; Rawlinson, William D. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Human cytomegalovirus (HCMV) causes severe sequelae in immunocompromised hosts. Current antiviral therapies have serious adverse effects, with treatment in many clinical settings problematic, making new therapeutic approaches necessary. We examined the in vitro efficacy of small interfering RNAs...

  • Inhibition of Hepatitis B Virus cccDNA by siRNA in Transgenic Mice. Li, Guiqiu; Jiang, Guotao; Lu, Juan; Chen, Shulan; Cui, Lanying; Jiao, Jundong; Wang, Yongchen // Cell Biochemistry & Biophysics;Jul2014, Vol. 69 Issue 3, p649 

    The elimination of viral covalently closed circular DNA (cccDNA) from the nucleus of infected hepatocytes is an obstacle to achieving sustained viral clearance during antiviral therapy of chronic hepatitis B virus (HBV) infection. The aim of our study was to determine whether treatment with...

  • Small Interfering RNA Inhibition of Andes Virus Replication. Chiang, Cheng-Feng; Albari┼ło, Cesar G.; Lo, Michael K.; Spiropoulou, Christina F. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Andes virus (ANDV) is the most common causative agent of hantavirus pulmonary syndrome (HPS) in the Americas, and is the only hantavirus associated with human-to-human transmission. Case fatality rates of ANDV-induced HPS are approximately 40%. There are currently no effective vaccines or...

  • Scion on a Stock Producing siRNAs of Potato Spindle Tuber Viroid (PSTVd) Attenuates Accumulation of the Viroid. Kasai, Atsushi; Sano, Teruo; Harada, Takeo // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Plants can attenuate the replication of plant viruses and viroids by RNA silencing induced by virus and viroid infection. In higher plants, silencing signals such as small interfering RNAs (siRNAs) produced by RNA silencing can be transported systemically through phloem, so it is anticipated...

  • Characterization of Rice Black-Streaked Dwarf Virus- and Rice Stripe Virus-Derived siRNAs in Singly and Doubly Infected Insect Vector Laodelphax striatellus. Li, Junmin; Andika, Ida Bagus; Shen, Jiangfeng; Lv, Yuanda; Ji, Yongqiang; Sun, Liying; Chen, Jianping // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Replication of RNA viruses in insect cells triggers an antiviral defense that is mediated by RNA interference (RNAi) which generates viral-derived small interfering RNAs (siRNAs). However, it is not known whether an antiviral RNAi response is also induced in insects by reoviruses, whose...

  • Ninety-Six-Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV-1 and Wild-Type Hepatitis B Virus. Bani-Sadr, F.; Palmer, P.; Scieux, C.; Molina, J. M. // Clinical Infectious Diseases;10/1/2004, Vol. 39 Issue 7, p1062 

    We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics